Why the study?
Does metoprolol readministration cause persistent acute adverse haemodynamic effects in patients with congestive heart failure on chronic treatment?
Does metoprolol readministration cause persistent acute adverse haemodynamic effects in patients with congestive heart failure on chronic treatment?
Despite the long-term benefits of beta-blockade in heart failure, each subsequent dose continues to produce acute, transient adverse haemodynamic effects.
Answers are grounded in this paper and cite their sources.
Acute hemodynamic worsening with metoprolol readministration persists after 3 months in heart failure; leaves open effects on long-term outcomes and optimal dosing.
OBJECTIVE: To determine whether the acute adverse haemodynamic effects of beta blockade in patients with congestive heart failure persist during chronic treatment. DESIGN: Sequential haemodynamic evaluation of heart failure patients at baseline and after three months of continuous treatment with the beta 1 selective antagonist metoprolol. SETTING: Cardiac care unit in university hospital. PATIENTS: 26 patients with moderate to severe congestive heart failure (New York Heart Association grade II to IV) and background treatment with digoxin, diuretics, and angiotensin converting enzyme inhibitors, and with a left ventricular ejection fraction < 25%. METHODS: Baseline variables included a six minute walk, maximum oxygen consumption, and right heart catheterisation. All patients received metoprolol 6.25 mg orally twice daily initially and the dose was gradually increased to a target of 50 mg twice daily. Haemodynamic measurements were repeated after three months of treatment, both before (trough) and after drug readministration. RESULTS: Long term metoprolol had functional, exercise, and haemodynamic benefits. It produced decreases in heart rate, pulmonary capillary wedge pressure, and systemic vascular resistance, and increases in cardiac index, stroke volume index, and stroke work index. However, when full dose metoprolol was readministered during chronic treatment, there was a reduction in cardiac index (from 2.8 (SD 0.46) to 2.3 (0.38) l/min/m2, p << 0.001) and stroke work index (from 31.4 (11.1) to 26.6 (10.0) g.m/m2, p < 0.001) and an increase in systemic vascular resistance (from 943 (192) to 1160 (219) dyn.s.cm-5, p << 0.001). CONCLUSIONS: Adverse haemodynamic effects of beta blockers in heart failure persist during chronic treatment, as shown by worsening haemodynamic indices with subsequent doses.
No takes yet. Share an insight, caveat, or question.
Kukin et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: